Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 15, Number 8—August 2009

Research

Increase in Pneumococcus Macrolide Resistance, United States

Stephen G. JenkinsComments to Author  and David J. Farrell
Author affiliations: Weill Cornell Medical College, New York, NY, USA (S.G. Jenkins); Quotient Bioresearch Ltd, London, UK (D.J. Farrell)

Main Article

Table 3

Antimicrobial susceptibility of erythromycin-resistant isolates, by genotype, year 6 (2005–2006) of the PROTEKT US surveillance study*

   Genotype    Amoxicillin−clavulanate
   Levofloxacin
   Telithromycin
   Susceptibility, %
   MIC, μg/mL
   Susceptibility, %
   MIC, μg/mL
   Susceptibility, %
   MIC, μg/mL
   S    I    R    MIC50    MIC90    S    I    R    MIC50    MIC90    S    I    R    MIC50    MIC90
   erm(B)†    96.2    0.9    2.9    0.12    2    98.2    0.2    1.6    1    1    99.1    0.7    0.2    0.03    0.12
   mef(A)‡    92.1    3.7    4.2    0.25    2    98.9    0.1    1.0    1    1    99.6    0.4    0    0.25    0.5
   erm(B) + mef(A)§    9.7    9.9    80.3    >8    >8    98.8    0.2    1.0    1    1    99.1    0.5    0.3    1    1

   *PROTEKT US, Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin, United States; S, susceptible; I, intermediate; R, resistant.
   †n = 448.
   ‡n = 1,282.
   §n = 575.

Main Article

TOP